KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2025)

Amneal Pharmaceuticals has reported Research & Development over the past 9 years, most recently at $34.8 million for Q4 2025.

  • Quarterly results put Research & Development at $34.8 million for Q4 2025, down 35.84% from a year ago — trailing twelve months through Dec 2025 was $186.2 million (down 2.38% YoY), and the annual figure for FY2025 was $186.2 million, down 2.38%.
  • Research & Development for Q4 2025 was $34.8 million at Amneal Pharmaceuticals, down from $63.4 million in the prior quarter.
  • Over the last five years, Research & Development for AMRX hit a ceiling of $63.4 million in Q3 2025 and a floor of $34.8 million in Q4 2025.
  • Median Research & Development over the past 5 years was $48.1 million (2021), compared with a mean of $46.9 million.
  • Biggest five-year swings in Research & Development: surged 47.67% in 2024 and later plummeted 35.84% in 2025.
  • Amneal Pharmaceuticals' Research & Development stood at $51.9 million in 2021, then dropped by 19.21% to $41.9 million in 2022, then rose by 9.97% to $46.1 million in 2023, then rose by 17.75% to $54.3 million in 2024, then crashed by 35.84% to $34.8 million in 2025.
  • The last three reported values for Research & Development were $34.8 million (Q4 2025), $63.4 million (Q3 2025), and $48.0 million (Q2 2025) per Business Quant data.